Journal
EXPERIMENTAL DERMATOLOGY
Volume 19, Issue 8, Pages 754-756Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0625.2010.01089.x
Keywords
etanercept; psoriasis; innate immunity; skin inflammation
Categories
Ask authors/readers for more resources
To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction > 50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-alpha) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available